Back
ImmuneOnco Plunges 12.6% Despite Phase III Trial Progress
Back
Stock News
Themes
ImmuneOnco Plunges 12.6% Despite Phase III Trial Progress
ImmuneOnco Plunges 12.6% Despite Phase III Trial Progress
Edgen Stock
·
Jan 21 2026, 15:42
Share to
Share to
Copy link
IMMUNEONCO-B
0.00%
source:
[1] ImmuneOnco (01541.HK) completes patient recruitment for Phase III clinical trial of core product IMM01
Recommend
Regentis Reports Breakthrough Cartilage Regeneration in 2-Year GelrinC Study
Jan 20 2026, 14:36
ServiceNow Taps OpenAI to Embed AI Agents in Enterprise Software
Jan 20 2026, 14:32
Bristol Myers Taps Microsoft AI for Lung Cancer Detection
Jan 20 2026, 14:26
Edgen Stock·Jan 21 2026, 15:42Edgen Stock·Jan 21 2026, 15:42
Edgen Stock·Jan 21 2026, 15:42